Human medicines European public assessment report (EPAR): Pomalidomide Teva, pomalidomide, Date of authorisation: 14/11/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 11, Status: Authorised

Minutes of the HMPC meeting 17-19 November 2025

Human medicines European public assessment report (EPAR): Koselugo, selumetinib, Date of authorisation: 17/06/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Abevmy, bevacizumab, Date of authorisation: 21/04/2021, Revision: 12, Status: Authorised

Questions and answers on Implementing Regulation (EU) 2025/1466: Amendment of Regulation (EU) No 520/2012 and Conclusion of the Signal Detection in EudraVigilance Pilot by marketing authorisation holders

Questions and answers on how to use a CEP in the context of a Marketing Authorisation Application or a Marketing Authorisation Variation

Human medicines European public assessment report (EPAR): Zirabev, bevacizumab, Date of authorisation: 14/02/2019, Revision: 18, Status: Authorised

ICH Q3E Extractables and leachables - scientific guideline